Sökning: "Leukemia : metabolism"
Visar resultat 1 - 5 av 34 avhandlingar innehållade orden Leukemia : metabolism.
1. CRISPR Screens Identify Candidate Therapeutic Targets in Leukemia
Sammanfattning : Acute myeloid leukemia (AML) is a complex hematological malignancy marked by proliferation of immature myeloid cells with a dismal 5-year survival. A major challenge is the persistence of leukemia stem cells (LSCs) after standard treatment, leading to relapse. LÄS MER
2. Targeting Nutrient Transporters in Acute Myeloid Leukemia
Sammanfattning : .... LÄS MER
3. Development of Gene Therapy for Hematopoietic Stem Cells using Lentiviral Vectors
Sammanfattning : Hematopoietic stem cells are an ideal target for genetic manipulation for the purpose of curing hematological disorders as they have the ability to develop into all blood lineages and to self-renew. In this study we demonstrate that lentiviral vectors, based on HIV-1, can efficiently transfer genes into human hematopoietic progenitor and stem cells as assessed following stem cell transplantation in immune compromised mice. LÄS MER
4. Prognostic markers in acute myeloid leukemia : A candidate gene approach
Sammanfattning : The standard treatment of acute myeloid leukemia (AML) consists of induction chemotherapy, most commonly daunorubicin together with the nucleoside analogue cytarabine (Ara-C), followed by consolidation chemotherapy and in selected cases allogenic stem cell transplantation (allo-SCT). Despite a high initial response rate, a considerable proportion of all AML cases eventually suffer from relapse and the five-year overall survival rate in patients >60 years is only around 15%. LÄS MER
5. Aspects on long-term treatment with tyrosine kinase inhibitors in Chronic myeloid leukemia
Sammanfattning : Chronic myeloid leukemia (CML) is caused by the tyrosine kinase activity of the oncoprotein BCR-ABL. The introduction of tyrosine kinase inhibitors (TKIs) targeting BCR-ABL has profoundly changed the prognosis of CML. Currently, there are three TKIs approved for treatment of CML, imatinib, nilotinib and dasatinib. LÄS MER